Main Menu

ICR-CTSU clinical trials

The ICR-CTSU manages a number of trials in different disease sites. Use the filter below to view trials for each cancer type:

Filter

Open to recruitment

AURORA

Aiming to understand the molecular aberrations in metastatic breast cancer.

c-TRAK TN

A randomised trial utilising ctDNA mutation tracking to detect minimal residual disease and trigger intervention in patients with moderate and high risk early stage triple negative breast cancer.

PHOENIX

A pre-surgical window of opportunity and post-surgical adjuvant biomarker study of DNA damage response inhibition and/or anti-PD-L1 immunotherapy in patients with neoadjuvant chemotherapy resistant residual triple negative breast cancer.

plasmaMATCH

A multiple parallel cohort, open-label, multicentre phase IIa clinical trial aiming to provide proof of principle efficacy for designated targeted therapies in patients with advanced breast cancer where the targetable mutation is identified through ctDNA screening.

PRIMETIME

Post-operative avoidance of radiotherapy: biomarker selection of women categorised to be in a very low risk group by IHC4+C.

UNIRAD

Randomized, double-blind, multicentre phase III trial evaluating the safety and benefit of adding everolimus to adjuvant hormone therapy in women with high risk of relapse, ER+ and HER2- primary breast cancer who remain free of disease after receiving at least 1 year of adjuvant hormone therapy.

In follow-up

ABC

UK Co-ordinating Committee on Cancer Research randomised trial of adjuvant endocrine therapy and chemotherapy in women with early breast cancer.

AZURE

Does adjuvant zoledronic acid reduce recurrence in patients with high risk localised breast cancer?

BASO DCIS II

Randomised trial testing observation (no radiotherapy) against radiotherapy in women with low risk completely excised ER+ ductal carcinoma in situ of the breast on adjuvant endocrine therapy.

BIG2-06 ALTTO

A randomised, multicentre, open label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2+/ErbB2+ primary breast cancer.

BIG4-11 APHINITY

A randomised, multicentre, double blind, placebo controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HER2+ primary breast cancer.

CORE

Conventional care versus Radioablation (stereotactic body radiotherapy) for extracranial oligometastases.

EPHOS-B

Effect of perioperative anti-HER2 therapy on early breast cancer study – biological phase.

FAST

Prospective randomised clinical trial testing 5.7 Gy and 6.0 Gy fractions of whole breast radiotherapy in terms of late normal tissue responses and tumour control.

FAST-Forward

Randomised clinical trial testing a 1 week course of curative whole breast radiotherapy against a standard 3 week schedule in terms of local cancer control and late adverse effects in patients with early breast cancer.

HERA

A randomised three arm multicentre comparison of 1 year and 2 years of trastuzumab (Herceptin®) versus no trastuzumab in women with HER2+ primary breast cancer who have completed adjuvant chemotherapy.

HOT

Randomised phase II trial of hyperbaric oxygen therapy for patients with chronic arm lymphoedema after radiotherapy for early breast cancer.

IMPORT HIGH

Randomised trial testing dose escalated intensity modulated radiotherapy for women treated by breast conservation surgery and appropriate systemic therapy for early breast cancer.

IMPORT LOW

Randomised trial testing intensity modulated and partial organ radiotherapy following breast conservation surgery for early breast cancer.

MA32

A phase III randomised trial of metformin versus placebo on recurrence and survival in early stage breast cancer

PALLET

A phase II randomised study evaluating the biological and clinical effects of the combination of palbociclib with letrozole as neoadjuvant therapy in post menopausal women with ER+ primary breast cancer.

PENELOPE-B

Phase III study evaluating palbociclib, a cyclin-dependent kinase 4/6 inhibitor, in patients with hormone receptor-positive, HER2-normal primary breast cancer with high relapse risk after neoadjuvant chemotherapy.

POETIC

POETIC is a randomised phase III multicentre trial in postmenopausal women with ER/PgR positive invasive breast cancer.

PYTHIA

Phase II study of palbociclib plus fulvestrant versus placebo plus fulvestrant for pre-treated patients with ER+/HER2- metastatic breast cancer.

REACT

A phase III multicentre double blind randomised trial of celecoxib versus placebo in primary breast cancer patients.

RIO

Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer.

SOFEA

A study of faslodex with or without concomitant arimidex versus exemestane following progression on non-steroidal aromatase inhibitors.

START

A randomised comparison of radiotherapy fractionation regimens after local excision or mastectomy, in order to standardise routine radiotherapy treatments throughout the NHS for women with early breast cancer.

TACT

A randomised trial of standard anthracycline based chemotherapy with fluorouracil, epirubicin and cyclophosphamide (FEC) or epirubicin and CMF (Epi-CMF) versus FEC followed by sequential docetaxel as adjuvant treatment for women with early breast cancer.

TACT2

Phase II, randomised controlled trial of accelerated adjuvant chemotherapy with capecitabine in early breast cancer.

TEXT

A phase III trial evaluating the role of exemestane plus gonadotropin releasing hormone analogue as adjuvant therapy for premenopausal women with endocrine responsive breast cancer.

TNT

Randomised phase III trial of carboplatin compared to docetaxel for patients with metastatic or recurrent locally advanced ER-, PR- and HER2- (triple negative) breast cancer.

TOPIC II

Trial of primary medical therapy for breast cancer.

UK HRT

UK randomised trial of hormone replacement therapy in women with a history of early stage breast cancer.

Closed

ACTION

Phase III randomised controlled trial testing the benefit and tolerability of adjuvant chemotherapy in patients aged 70 and over with early stage ER negative or ER weakly positive breast cancer.

DEVA

A multicentre randomised trial of sequential epirubicin and docetaxel versus epirubicin in node positive postmenopausal breast cancer.

FEC trial

Two randomised trials comparing chemotherapy regimens CMF and FEC in node positive and node negative primary breast cancer.

ICCG High Dose Study

Randomised trial of high dose therapy using cyclophosphamide, thiotepa and carboplatin in primary breast cancer patients with 4 or more histologically involved positive nodes.

ICCG HMFEC Trial

FE 50 C versus FE 75 C with or without sequential hormone therapy in women with node positive premenopausal breast cancer.

ICCG IES

The Intergroup Exemestane Study (IES) is a randomised double-blind trial in postmenopausal women with primary breast cancer who have received adjuvant tamoxifen for 2-3 years, comparing subsequent adjuvant exemestane treatment with further tamoxifen to complete a total of 5 years endocrine therapy.

ICCG Neocent

Neoadjuvant study of chemotherapy versus endocrine therapy in postmenopausal patients with primary breast cancer

MAPLE

Double-blind short term pre-surgical study to assess the molecular antiproliferative predictors of lapatinib’s effects in breast cancer.

QUEST

Two phase III, multicentre, randomised trials to assess the impact of the type (trial A) and timing (trial B) of breast reconstruction on quality of life following mastectomy for early breast cancer.

SOFT

SOFT is a phase III, randomised, multicentre study evaluating the role of ovarian function suppression and the role of exemestane as adjuvant therapies for pre-menopausal women with endocrine responsive breast cancer.

TOPIC I

Trial of primary infusional chemotherapy.

TRAFIC

Trial of adjuvant 5FU infusional chemotherapy.

Division of Clinical Studies

The division carries out or coordinates high-quality trials and translational research at both an early phase – typically to test new targeted drugs – and a later stage.

Current vacancies